Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Innovent's PD-1 Inhibitor Meets Endpoint as First-Line Gastric Cancer Therapy

publication date: Aug 17, 2021

Suzhou Innovent Bio reported that its PD-1 inhibitor met an overall survival endpoint in a Phase III trial as a first-line treatment for gastric cancer. Sintilimab is marketed as Tyvyt® in China. The Phase III trial evaluated sintilimab in combination with chemotherapy and compared to chemotherapy alone. The trial enrolled patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. Innovent said sintilimab is the first PD-1 inhibitor to show efficacy in gastric cancer. It is approved for four types of cancer in China. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:

 


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital